КЛИНИКО-ИММУНОЛОГИЧЕСКИЕ ВЗАИМОСВЯЗИ У ПАЦИЕНТОВ С ДЕПРЕССИВНЫМ ЭПИЗОДОМ
Оригинальная статья
Дата публикации: июня 27, 2023
Ключевые слова
депрессия
нейровоспаление
иммунологические маркеры
нейровоспаление
иммунологические маркеры
Как цитировать
Касьянова А. А., Соболевская П. А., Чурилов Л. П., Конюшенко К. К., Петрова Н. Н. КЛИНИКО-ИММУНОЛОГИЧЕСКИЕ ВЗАИМОСВЯЗИ У ПАЦИЕНТОВ С ДЕПРЕССИВНЫМ ЭПИЗОДОМ // Кремлевская медицина. Клинический вестник. 2023. Т. № 2. С. 22-26.
Аннотация
Связь между депрессией и иммунной дисфункцией носит двунаправленный характер. Выявление биомаркеров, связанных с иммунологическим профилем, позволит уточнить механизмы развития депрессии, указав таким образом на возможные новые психофармакологические мишени лечения данных расстройств. Цель. Провести поисковый анализ связи иммунологических показателей с клиническими и психометрическими характеристиками у пациентов с депрессией. Материалы и методы. В исследование было включено 20 человек: 10 пациентов с депрессивным эпизодом (медианный возраст – 29.5 [23.0–37.5] лет) и 10 участников без психических расстройств (28.5 [24.0–32.0] лет). Все участники исследования были обследованы с помощью полуструктурированного диагностического интервью MINI, карты исследования и психометрических шкал. Концентрации интерлейкина (ИЛ) 1β, ИЛ-2, ИЛ-6, фактора некроза опухоли альфа (ФНО-α) и С-реактивного белка (СРБ) в периферической крови определяли методом иммуноферментного анализа. Результаты. Пациенты с депрессией имели более высокие уровни ИЛ-6 (пг/мл) в сравнении с участниками без психических расстройств (2 [1.1–2.2] в сравнении с 0.8 [0.5–1.2]; p = 0.02). Уровни ФНО-α, ИЛ-2, ИЛ-1β и СРБ не различались между данными группами (p > 0.05). ИЛ-6 имел значимые средние положительные корреляции с уровнем депрессии по MADRS (ρ = 0.6157344; p = 0.00384) и уровнем тревоги по HADS-A (ρ = 0.5045433; p = 0.02329). На уровне тенденции к значимости ИЛ-6 имел слабые средние положительные корреляции с уровнем депрессии по HADS-D (ρ = 0.4142998; p = 0.06935). Заключение. В рамках проведенного исследования были получены новые данные о связи иммунологических показателей с клиническими и психометрическими характеристиками при депрессииЛитература
1. Eyre H. et al. Neuroplastic changes in depression: a role for the immune system // Psychoneuroendocrinology. – 2012. – V. 37. – № 9. – P. 1397–1416.
2. Smith R.S. The macrophage theory of depression // Med Hypotheses. – 1991. – V. 35. – № 4. – P. 298–306.
3. Beurel E. et al. The bidirectional relationship of depression and inflammation: double trouble // Neuron. – 2020. – V. 107. – № 2. – P. 234–256.
4. Wohleb E.S. et al. Integrating neuroimmune systems in the neurobiology of depression // Nat Rev Neurosci. – 2016. – V. 17. – № 8. – P. 497–511.
5. Cruz-Pereira J.S. et al. Depression's unholytrinity: dysregulated stress, immunity, and the microbiome // Ann Rev Psychol. – 2020. – V. 71. – P. 49–78.
6. D'Mello C. et al. Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain // J Neurosci. – 2015. – V. 35. – № 30. – P. 10821–10830.
7. Goldsmith D.R. et al. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression // Mol Psychiatry. – 2016. – V. 21. – № 12. – P. 1696–1709.
8. Mao R. et al. Different levels of pro-and anti-inflammatory cytokines in patients with unipolar and bipolar depression // J Affect Dis. – 2018. – V. 237. – P. 65–72.
9. Rosenblat J.D. et al. Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications // Brain Sci. – 2017. – V. 7. – № 11. – P. 144.
10. Köhler‐Forsberg O. et al. Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials // Acta Psychiatrica Scandinavica. – 2019. – V. 139. – № 5. – P. 404–419.
11. Liu C. et al. Cytokines: from clinical significance to quantification // Adv Sci. – 2021. – V. 8. – № 15. – P. 2004433.
12. MacGillivray D.M. et al. The role of environmental factors in modulating immune responses in early life // Front Immunol. – 2014. – V. 5. – P. 434.
13. Benedetti F. et al. Neuroinflammation in bipolar depression // Front Psychiatry. – 2020. – V. 11. – P. 71.
14. Lu Y.R. et al. High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder // Medicine. – 2019. – V. 98. – № 7.
15. Nobis A. et al. Peripheral markers of depression // J Clin Med. – 2020. – V. 9. – № 12. – P. 3793.
16. Brydges C.R. et al. Metabolomic and inflammatory signatures of symptom dimensions in major depression // Brain Behav Immun. – 2022. – V. 102. – P. 42–52.
17. Badini I. et al. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption // Psychol Med. – 2022. – V. 52. – № 4. – P. 726–736.
18. Wiener C.D. et al. Interleukin-6 and interleukin-10 in mood disorders: a population-based study // Psychiatry Res. – 2019. – V. 273. – P. 685–689.
19. Howren M.B. et al. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis // Psychosom Med. – 2009. – V. 71. – № 2. – P. 171–186.
20. Young J.J. et al. A review of the relationship between proinflammatory cytokines and major depressive disorder // J Affect Dis. – 2014. – V. 169. – P. 15–20.
21. Brundin L. et al. The role of inflammation in suicidal behaviour // Acta Psychiatrica Scandinavica. – 2015. – V. 132. – № 3. – P. 192–203.
22. Майорова М.А. и др. Взаимосвязь аутоиммунных процессов, эндокринных нарушений и депрессии // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. – 2020. – № 1. – С. 8–19. [Mayorova M.A. et al. The relationship of autoimmune processes, endocrine disorders and depression // Review of Psychiatry and Medical Psychology named after V.M. Bekhterev. – 2020. – № 1. – P. 8–19. In Russian].
23. Kopschina Feltes P. et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy // J Psychopharmacol. – 2017. – V. 31. – № 9. – P. 1149–1165.
24. Kohler O. et al. Inflammation in depression and the potential for anti-inflammatory treatment // Curr Neuropharmacol. – 2016. – V. 14. – № 7. – P. 732–742.
25. Uher R. et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline // Am J Psychiatry. – 2014. – V. 171. – № 12. – P. 1278–1286.
26. Bai S. et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials // J Neurol Neurosurg Psychiatry. – 2020. – V. 91. – № 1. – P. 21–32.
27. Rosenblat J.D. et al. Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis // Bipolar Dis. – 2016. – V. 18. – № 2. – P. 89–101.
28. Hede V. et al. Treating psychiatric symptoms and disorders with non-psychotropic medications // Dialogues Clin Neurosci. – 2019. – V. 21. - № 2. – P. 193–201.
29. Köhler-Forsberg O. et al. Do statins have antidepressant effects? // CNS Drugs. – 2017. – V. 31. – № 5. – P. 335–343.
30. Незнанов Н.Г. и др. Атипичная депрессия: от фенотипа к эндофенотипу // Социальная и клиническая психиатрия. – 2016. – Т. 26. – № 3. – С. 5–16. [Neznanov N.G. et al. Atypical depression: from phenotype to endophenotypes // Social and clinical psychiatry. – 2016. – V. 26. – № 3. – P. 5–16. In Russian].
31. Dean C.E. The death of specificity in psychiatry: cheers or tears? // Perspect Biol Med. – 2012. – V. 55. – № 3. – P. 443–460.
2. Smith R.S. The macrophage theory of depression // Med Hypotheses. – 1991. – V. 35. – № 4. – P. 298–306.
3. Beurel E. et al. The bidirectional relationship of depression and inflammation: double trouble // Neuron. – 2020. – V. 107. – № 2. – P. 234–256.
4. Wohleb E.S. et al. Integrating neuroimmune systems in the neurobiology of depression // Nat Rev Neurosci. – 2016. – V. 17. – № 8. – P. 497–511.
5. Cruz-Pereira J.S. et al. Depression's unholytrinity: dysregulated stress, immunity, and the microbiome // Ann Rev Psychol. – 2020. – V. 71. – P. 49–78.
6. D'Mello C. et al. Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain // J Neurosci. – 2015. – V. 35. – № 30. – P. 10821–10830.
7. Goldsmith D.R. et al. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression // Mol Psychiatry. – 2016. – V. 21. – № 12. – P. 1696–1709.
8. Mao R. et al. Different levels of pro-and anti-inflammatory cytokines in patients with unipolar and bipolar depression // J Affect Dis. – 2018. – V. 237. – P. 65–72.
9. Rosenblat J.D. et al. Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications // Brain Sci. – 2017. – V. 7. – № 11. – P. 144.
10. Köhler‐Forsberg O. et al. Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials // Acta Psychiatrica Scandinavica. – 2019. – V. 139. – № 5. – P. 404–419.
11. Liu C. et al. Cytokines: from clinical significance to quantification // Adv Sci. – 2021. – V. 8. – № 15. – P. 2004433.
12. MacGillivray D.M. et al. The role of environmental factors in modulating immune responses in early life // Front Immunol. – 2014. – V. 5. – P. 434.
13. Benedetti F. et al. Neuroinflammation in bipolar depression // Front Psychiatry. – 2020. – V. 11. – P. 71.
14. Lu Y.R. et al. High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder // Medicine. – 2019. – V. 98. – № 7.
15. Nobis A. et al. Peripheral markers of depression // J Clin Med. – 2020. – V. 9. – № 12. – P. 3793.
16. Brydges C.R. et al. Metabolomic and inflammatory signatures of symptom dimensions in major depression // Brain Behav Immun. – 2022. – V. 102. – P. 42–52.
17. Badini I. et al. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption // Psychol Med. – 2022. – V. 52. – № 4. – P. 726–736.
18. Wiener C.D. et al. Interleukin-6 and interleukin-10 in mood disorders: a population-based study // Psychiatry Res. – 2019. – V. 273. – P. 685–689.
19. Howren M.B. et al. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis // Psychosom Med. – 2009. – V. 71. – № 2. – P. 171–186.
20. Young J.J. et al. A review of the relationship between proinflammatory cytokines and major depressive disorder // J Affect Dis. – 2014. – V. 169. – P. 15–20.
21. Brundin L. et al. The role of inflammation in suicidal behaviour // Acta Psychiatrica Scandinavica. – 2015. – V. 132. – № 3. – P. 192–203.
22. Майорова М.А. и др. Взаимосвязь аутоиммунных процессов, эндокринных нарушений и депрессии // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. – 2020. – № 1. – С. 8–19. [Mayorova M.A. et al. The relationship of autoimmune processes, endocrine disorders and depression // Review of Psychiatry and Medical Psychology named after V.M. Bekhterev. – 2020. – № 1. – P. 8–19. In Russian].
23. Kopschina Feltes P. et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy // J Psychopharmacol. – 2017. – V. 31. – № 9. – P. 1149–1165.
24. Kohler O. et al. Inflammation in depression and the potential for anti-inflammatory treatment // Curr Neuropharmacol. – 2016. – V. 14. – № 7. – P. 732–742.
25. Uher R. et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline // Am J Psychiatry. – 2014. – V. 171. – № 12. – P. 1278–1286.
26. Bai S. et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials // J Neurol Neurosurg Psychiatry. – 2020. – V. 91. – № 1. – P. 21–32.
27. Rosenblat J.D. et al. Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis // Bipolar Dis. – 2016. – V. 18. – № 2. – P. 89–101.
28. Hede V. et al. Treating psychiatric symptoms and disorders with non-psychotropic medications // Dialogues Clin Neurosci. – 2019. – V. 21. - № 2. – P. 193–201.
29. Köhler-Forsberg O. et al. Do statins have antidepressant effects? // CNS Drugs. – 2017. – V. 31. – № 5. – P. 335–343.
30. Незнанов Н.Г. и др. Атипичная депрессия: от фенотипа к эндофенотипу // Социальная и клиническая психиатрия. – 2016. – Т. 26. – № 3. – С. 5–16. [Neznanov N.G. et al. Atypical depression: from phenotype to endophenotypes // Social and clinical psychiatry. – 2016. – V. 26. – № 3. – P. 5–16. In Russian].
31. Dean C.E. The death of specificity in psychiatry: cheers or tears? // Perspect Biol Med. – 2012. – V. 55. – № 3. – P. 443–460.